Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

David R. Gandara; Joachim von Pawel; Julien Mazieres; Richard Sullivan; Åslaug Helland; Ji Youn Han; Santiago Ponce Aix; Achim Rittmeyer; Fabrice Barlesi; Toshio Kubo; Keunchil Park; Jerome Goldschmidt; Mayank Gandhi; Cindy Yun; Wei Yu; Christina Matheny; Pei He; Alan Sandler; Marcus Ballinger; Louis Fehrenbacher

doi:10.1016/J.JTHO.2018.08.2027

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

David R. Gandara
, Joachim von Pawel
, Julien Mazieres
, Richard Sullivan
, Åslaug Helland
, Ji Youn Han
, Santiago Ponce Aix
, Achim Rittmeyer
, Fabrice Barlesi
, Toshio Kubo
, Keunchil Park
, Jerome Goldschmidt
, Mayank Gandhi
, Cindy Yun
, Wei Yu
, Christina Matheny
, Pei He
, Alan Sandler
, Marcus Ballinger
, Louis Fehrenbacher

University of California, Davis
Asklepios-Fachkliniken München-Gauting, Gauting, Germany
University of Toulouse
Auckland City Hospital
Oslo University Hospital
National Cancer Center, Ilsandong-gu, Goyang, Korea
Hospital Universitario 12 de Octubre, Madrid, Spain
Lungenfachklinik Immenhausen, Immenhausen, Germany
Aix-Marseille University
Okayama University
Samsung Medical Center
Blue Ridge Cancer Care, Blacksburg, Virginia; US Oncology Research, The Woodlands, Texas
Genentech
Kaiser Permanente

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	12
DOIs	https://doi.org/10.1016/J.JTHO.2018.08.2027
State	Published - Dec 1 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1016/J.JTHO.2018.08.2027License: Unspecified

Cite this

Gandara, D. R., von Pawel, J., Mazieres, J., Sullivan, R., Helland, Å., Han, J. Y., Aix, S. P., Rittmeyer, A., Barlesi, F., Kubo, T., Park, K., Goldschmidt, J., Gandhi, M., Yun, C., Yu, W., Matheny, C., He, P., Sandler, A., Ballinger, M., & Fehrenbacher, L. (2018). Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Journal of Thoracic Oncology, 13(12). https://doi.org/10.1016/J.JTHO.2018.08.2027

Gandara, DR, von Pawel, J, Mazieres, J, Sullivan, R, Helland, Å, Han, JY, Aix, SP, Rittmeyer, A, Barlesi, F, Kubo, T, Park, K, Goldschmidt, J, Gandhi, M, Yun, C, Yu, W, Matheny, C, He, P, Sandler, A, Ballinger, M & Fehrenbacher, L 2018, 'Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study', Journal of Thoracic Oncology, vol. 13, no. 12. https://doi.org/10.1016/J.JTHO.2018.08.2027

@article{364ea0a5e586483f8087855e9d722dc6,

title = "Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study",

author = "Gandara, \{David R.\} and \{von Pawel\}, Joachim and Julien Mazieres and Richard Sullivan and {\AA}slaug Helland and Han, \{Ji Youn\} and Aix, \{Santiago Ponce\} and Achim Rittmeyer and Fabrice Barlesi and Toshio Kubo and Keunchil Park and Jerome Goldschmidt and Mayank Gandhi and Cindy Yun and Wei Yu and Christina Matheny and Pei He and Alan Sandler and Marcus Ballinger and Louis Fehrenbacher",

note = "Introduction Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK study of atezolizumab (anti-programmed death-ligand 1) versus docetaxel in advanced NSCLC, overall survival (OS) benefit with atezolizumab was observed in the overall patient population, without improvement in objective response rate (ORR) or progression-free survival (PFS).",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/J.JTHO.2018.08.2027",

language = "American English",

volume = "13",

journal = "Journal of Thoracic Oncology",

number = "12",

}

TY - JOUR

T1 - Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

AU - Gandara, David R.

AU - von Pawel, Joachim

AU - Mazieres, Julien

AU - Sullivan, Richard

AU - Helland, Åslaug

AU - Han, Ji Youn

AU - Aix, Santiago Ponce

AU - Rittmeyer, Achim

AU - Barlesi, Fabrice

AU - Kubo, Toshio

AU - Park, Keunchil

AU - Goldschmidt, Jerome

AU - Gandhi, Mayank

AU - Yun, Cindy

AU - Yu, Wei

AU - Matheny, Christina

AU - He, Pei

AU - Sandler, Alan

AU - Ballinger, Marcus

AU - Fehrenbacher, Louis

N1 - Introduction Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK study of atezolizumab (anti-programmed death-ligand 1) versus docetaxel in advanced NSCLC, overall survival (OS) benefit with atezolizumab was observed in the overall patient population, without improvement in objective response rate (ORR) or progression-free survival (PFS).

PY - 2018/12/1

Y1 - 2018/12/1

UR - http://europepmc.org/abstract/MED/30217492

U2 - 10.1016/J.JTHO.2018.08.2027

DO - 10.1016/J.JTHO.2018.08.2027

M3 - Article

VL - 13

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 12

ER -

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Disciplines

Access to Document

Other files and links

Cite this